Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.06
<$0.01(4.95%)
At close: 4:00 PM EDT
$0.06
<$0.01(4.95%)
Day’s Range― - ―
52-Week Range$0.05 - $6.66
Previous CloseN/A
Volume53.96K
Average Volume (3M)97.64K
Market Cap
$556.31K
Enterprise Value$9.99
Total Cash (Recent Filing)$31.00K
Total Debt (Recent Filing)$8.91M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding9,493,287
10 Day Avg. Volume69,254
30 Day Avg. Volume97,636
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams: OTC Products And DiagnosticsOperating both consumer OTC product sales and clinical diagnostic testing gives the company structural revenue diversification across channels and payors. This lowers single-market concentration risk, enables cross-channel distribution flexibility, and can stabilize cash flow if one segment underperforms.
Gross Profit Returned To PositiveRestoring positive gross profit indicates pricing, product-mix, or cost-of-goods improvements that re-establish basic unit economics. While overall profitability remains weak, positive gross margin is a prerequisite for future operating leverage and sustainable margin recovery if revenue stabilizes.
Sizeable Assets Relative To Absolute Debt LevelHaving substantial tangible assets (~$58.7M) with a modest absolute debt load (~$9.5M) provides optionality: assets can be monetized or pledged to raise liquidity, and the balance-sheet contains resources to support restructuring or strategic transactions to preserve operations.
Bears Say
Multi-year Revenue CollapseA dramatic, multi-year decline in revenue destroys scale, weakens retailer and payor relationships, and leaves fixed-costs disproportionately high versus sales. Rebuilding meaningful topline will require new products, contracts, or distribution wins and is a structural challenge.
Negative Equity And Elevated Leverage RiskNegative shareholders' equity signals erosion of the capital base and raises refinancing and covenant risks. It constrains the company's ability to access traditional financing, undermines supplier confidence, and limits strategic flexibility absent recapitalization.
Persistent Cash Burn And Weak Cash GenerationSustained negative operating and free cash flow requires external funding or asset sales to sustain operations. Continued cash burn constrains investment in product development or distribution, increases dilution/refinancing risk, and leaves limited runway if revenue does not recover.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.05 and its highest was $6.66 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $556.31K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were Prophase Labs’s earnings last quarter?
Currently, no data Available
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 9,493,287 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
37.75%
Insiders
0.23% Mutual Funds
0.89% Other Institutional Investors
61.13% Public Companies and
Individual Investors